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ABSTRACT 
Objective Tobacco smoking increases the risk of gastroesophageal reflux symptoms (GERS), but 
whether tobacco smoking cessation improves GERS is unclear. The aim of this study was to clarify if 
tobacco smoking cessation improves GERS. 
Design The study was based on the Nord-Trøndelag health study (the HUNT study), a prospective 
population-based cohort study conducted from 1995-1997 to 2006-2009 in Nord-Trøndelag County, 
Norway. All residents of the county from 20 years of age were invited. The study included 29,610 
individuals (61% response rate) who reported whether they had heartburn or acid regurgitation. The 
association between tobacco smoking cessation and improvement in GERS was assessed by logistic 
regression, providing odds ratios (ORs) with 95% confidence intervals (CIs). The analyses were 
stratified by antireflux medication, and the results were adjusted for sex, age, body mass index (BMI), 
alcohol consumption, education, and physical exercise. Subgroup analyses were also stratified by 
BMI. 
Results Among individuals using antireflux medication at least weekly, cessation of daily tobacco 
smoking was associated with improvement in GERS from severe to no or minor complaints (adjusted 
OR 1.78, 95% CI 1.07 to 2.97), compared with persistent daily smoking. This association was present 
among individuals within the normal range of BMI (OR 5.67, 95% CI 1.36 to 23.64), but not among 
overweight individuals. There was no association between tobacco smoking cessation and GERS 
status among individuals with minor GERS or individuals using antireflux medication less than weekly. 
Conclusion Tobacco smoking cessation was associated with improvement in severe GERS only in 
individuals of normal BMI using antireflux medication at least weekly, but not in other individual with 
GERS. 
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STUDY HIGHLIGHTS 
1) What is current knowledge 
 Gastroesophageal reflux symptoms (GERS) are prevalent in Western populations and 
associated with reduced health related quality of life and increased risk of esophageal 
adenocarcinoma. 
 Tobacco smoking is associated with an increased the risk of GERS. 
 The effect of tobacco smoking cessation on GERS is not clear. 
 
2) What is new here 
 This study did not find any association between tobacco smoking cessation and improvement 
in GERS in individuals not using regular antireflux medication. 
 Tobacco smoking cessation was associated with an improvement in severe GERS in 
individuals of normal weight using regular antireflux medication. 
 Tobacco smoking cessation was associated with an increased chance of treatment success 
with regular use of antireflux medication in severe GERS. 
 This study suggests that tobacco smoking cessation might be beneficial in normal weight 
patients suffering from gastroesophageal reflux. 
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MANUSCRIPT TEXT 
INTRODUCTION 
Tobacco smoking is associated with an increased risk of gastroesophageal reflux symptoms (GERS) 
according to several population-based studies from Western countries.(1-9) The odds ratios (ORs) of 
GERS among smokers compared to non-smokers have been in the range of 1.3 to 2.5. Tobacco 
smoking increases the risk of GERS by reducing the lower esophageal sphincter pressure, facilitating 
gastric acid to reach the esophagus,(10-12) and reducing the salivary bicarbonate secretion, which 
neutralizes the acidity of the gastric contents.(13, 14) In addition, both GERS and tobacco smoking 
are independently associated with an increased risk of adenocarcinoma of the esophagus and 
esophagogastric junction.(15-19) Two recent reviews on the effect of lifestyle changes on 
gastroesophageal reflux disease (GERD) concluded that the evidence to date does not support an 
improvement in GERD after cessation of tobacco use.(20, 21) However, in the available studies, only 
the very short-term effect of smoking cessation on GERD outcomes was evaluated.(22-24) Our 
hypothesis is that tobacco smoking cessation improves GERS. The aim of this study was to clarify if 
there is an association between tobacco smoking cessation and improvement in GERS in a large and 
population-based study with long follow-up. 
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METHODS 
Study design, setting and participants 
The study was based on a large population-based health study, the Nord-Trøndelag health study (the 
HUNT study), which we have used previously for epidemiological studies of GERS.(6, 25-27) The 
HUNT study is based on a series of health surveys where the entire population of Nord-Trøndelag 
County, Norway, from 20 years of age has been invited to participate. The first survey was conducted 
in 1984-1986 (HUNT 1), the second survey in 1995-1997 (HUNT 2), and the third survey in 2006-2008 
(HUNT 3). In all surveys a basic questionnaire was accompanying the invitation letter and the 
participants were asked to meet at screening stations for clinical and laboratory examinations. A 
short questionnaire (Mini-Q) was sent to non-participants after HUNT 3 in 2009 and those who 
responded to the Mini-Q were also included in our study. The questionnaires and examinations 
included a wide range of health related topics.(28) 
 
Assessment of the outcome gastroesophageal reflux symptoms 
In HUNT 2 and HUNT 3/Mini-Q, GERS status of the participants was defined based on the 
participants’ response to the following question: ‘To what degree have you had heartburn or acid 
regurgitation during the previous 12 months?’ The question had three response alternatives: ‘No 
complaints’, Minor complaints’, or ‘Severe complaints’. Improvement in GERS status from severe 
GERS in HUNT 2 to no or minor GERS in HUNT 3/Mini-Q was defined as the study outcome, while 
severe GERS at both time points (stable GERS) were defined as reference. We have previously 
validated this GERS question and found that 25% to 31% of those reporting minor GERS and 95% to 
98% of those reporting severe GERS had at least weekly complaints.(25) This suggests that the 
majority of those reporting severe GERS actually have GERD according to the Montreal definition and 
classification of GERD.(25, 26, 29) 
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Assessment of the exposure tobacco smoking 
In HUNT 2, the participants were asked about their tobacco smoking status by answering yes or no to 
these questions: ‘Have you ever smoked daily?’, ‘Do you smoke cigarettes daily?’, ‘Do you smoke 
cigars or cigarillos daily?’, and ‘Do you smoke pipe daily?’ In HUNT 3/Mini-Q, the participants were 
asked: ‘Do you smoke?’ The response alternatives to this question were: ‘No, I have never smoked’, 
‘No, I have quit smoking’, ‘Yes, cigarettes occasionally (parties/vacation, not daily)’, or ‘Yes, cigarettes 
daily’. Those who quitted daily tobacco smoking or reduced daily smoking to only occasional smoking 
between HUNT 2 and HUNT 3/Mini-Q were defined as ‘exposed’ to tobacco smoking cessation, and 
those who were persistent daily tobacco smokers at both time points were regarded as ‘unexposed’ 
to such cessation. 
 
Assessment of co-variables 
Co-variables were selected based on their known association with GERS: sex, age, alcohol 
consumption, education, physical exercise, body mass index (BMI), and antireflux medication. Data 
on sex and age at participation were recorded at each survey. Average frequency of alcohol 
consumption and physical exercise was reported through questionnaires in HUNT 3/Mini-Q. Years of 
education were reported through questionnaires in HUNT 2. BMI was assessed by objectively 
measuring height and body weight under standardized conditions and by trained personnel at the 
screening stations in HUNT 2 and HUNT 3, while in Mini-Q height and weight were reported by the 
responders. BMI was calculated as body weight in kilograms divided by the square height in meters 
(kg/m2). Antireflux medication included proton pump inhibitors (PPIs), histamine-2-reseptor 
antagonists (H2RAs), and antacids. In Norway, the prescription rules have until 2010 demanded a 
prescription from a physician to get PPIs or H2RAs, except small packages of low dose H2RAs which 
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have been available over the counter (OTC). In this study, information was gathered on the 
participants’ use of prescribed antireflux medication through the Norwegian Prescription Database 
(NorPD). The NorPD was established in 2004, and all prescribed medications from all Norwegian 
pharmacies were by legislation reported to the NorPD. From the NorPD data, the average use of 
prescribed antireflux medication was estimated based on number of tablets prescribed during the 
HUNT 3 data collection period (2006-2008). In addition, the questionnaires in HUNT 3 included an 
assessment of OTC medication use against several complaints, including heartburn or acid 
regurgitation. The question was: ‘How often have you used over the counter medication against the 
following complaints during the last month?’ The participants responded with one of four 
alternatives to this question: ‘Rare/never’, ‘1-3 times/week’, ‘4-6 times/week’, or ‘Daily’. Thus, the 
two data sources were complementary regarding the use of antireflux medication. There was no 
information on antireflux medication available during the HUNT 2 period. 
 
Statistical analysis 
Response rates were calculated from those eligible to participate at each survey, excluding those 
who were no longer residents in the county or had died. The association between tobacco smoking 
cessation (exposure) and GERS status (outcome) was assessed by multivariable logistic regression. 
Based on acknowledged criteria of a confounding factor, antireflux medication should not be 
included in the regression model, but instead be assessed as an effect modifier.(30) To account for 
the effect of antireflux medication on GERS, the analyses were stratified by the use of antireflux 
medication, no or less than weekly use and at least weekly use, and the results were reported for 
each stratum separately. Participants with missing information on antireflux medication were 
analyzed as using no or less than weekly antireflux medication, because in the NorPD data it was not 
possible to distinguish between those with truly missing data and those who did not receive a 
prescription. Secondary analyses were also stratified by BMI using the categories defined by the 
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World Health Organization (WHO): <18.5 units (underweight), 18.5-24.9 units (normal weight), 25.0-
29.9 units (pre-obese), and ≥30.0 units (obese).(31) To account for other potential confounders in the 
association between tobacco smoking and GERS, a continuous variable for age and categorical 
variables for sex, alcohol consumption (<weekly or ≥weekly), education (≤12 years or >12 years), and 
physical exercise (<weekly or ≥weekly) were included in the regression model. The statistical analyses 
were performed using Stata/IC 12.1 by StataCorp LP. 
 
Study approval 
The study was approved by the Regional Committee for Medical and Health Research Ethics, Central-
Norway (ID 4.2009.328).
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RESULTS 
Participants 
We have previously published a complete flowchart of the participants.(26) In HUNT 2 and HUNT 
3/Mini-Q, 58,869 individuals (64% response rate) and 44,997 individuals (49%) reported GERS status, 
respectively. Among these, the 29,610 individuals (61%) who reported GERS status at both time 
points were eligible. The average follow-up time was approximately 11 years. Among the 1553 
participants with severe GERS (5%) in HUNT 2, the 486 (31%) who were daily tobacco smokers were 
included in the present study. Of these participants, 182 quitted smoking and 31 reduced to 
occasional smoking. In total, 213 (44%) were previous daily smokers while 251 (52%) were persistent 
daily smokers in HUNT 3/Mini-Q. In both these groups, about 60% were using antireflux medication 
at least weekly (Figure 1). The mean BMI was similar between the groups, but obesity was less 
common among the persistent daily smokers. Compared to the previous daily smokers, the 
persistent daily smokers were characterized by higher female representation, lower mean age, lower 
education, lower level of physical exercise, and lower alcohol consumption (Table 1). 
 
Associations 
Among the daily tobacco smokers with severe GERS in HUNT 2 using no or less than weekly antireflux 
medication, there was no statistically significant association between tobacco smoking cessation and 
GERS status (adjusted OR 0.95, 95% CI 0.39 to 2.30), compared with persistent daily smoking (Table 
2). However, among the daily tobacco smokers with severe GERS in HUNT 2 using at least weekly 
antireflux medication, tobacco smoking cessation was associated with an improvement in GERS 
status from severe to no or minor complaints (adjusted OR 1.78, 95% CI 1.07 to 2.97), compared with 
persistent daily smoking (Table 2). Secondary, subgroup analyses found that the association only was 
present among individuals within the normal weight range (adjusted OR 5.67, 95% CI 1.36 to 23.64), 
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but not among overweight individuals (Table 3 and Figure 2). There was no association between 
tobacco smoking cessation and GERS status among individuals with minor GERS in HUNT 2 (data not 
shown). 
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DISCUSSION 
This study found that tobacco smoking cessation was associated with an improvement in severe 
GERS among normal weight individuals using antireflux medication at least weekly. There was, 
however, no such pattern in individuals with minor GERS, overweight, or those using antireflux 
medication less than weekly. 
 
Strengths of this study include the population-based design, reducing selection bias and increasing 
generalizability compared with clinic-based studies. Except for slightly lower average income and 
education and lack of a large city, the population of Nord-Trøndelag County is representative of the 
Norwegian population at large.(28, 32)  In addition, the prospective design circumvents recall bias 
and the wide range of variables assessed, including antireflux medication, makes adjustments for 
relevant confounders possible. Limitations include the inherent arbitrary definition of GERD, reducing 
the accuracy of identifying individuals with true GERD, probably leading to some misclassification. 
Misclassification is also possible among the exposure and co-variables, as the variables were 
dichotomized. In addition, the associations found were only modest and residual confounding can 
never be totally excluded in observational research. Loss to follow-up may introduce selection and 
survival bias, but such potential biases are probably small as a previous publication has shown that 
there was virtually no difference in the distribution of the study variables between all the HUNT 2 
participants (N=58,869) and the cohort who was followed up from HUNT 2 to HUNT 3 /Mini-Q 
(N=29,610).(27) Due to the observational design, causal relationships cannot be claimed. As there 
were low numbers of missing data among the participants (Table 1), complete case analyses were 
performed. 
 
The three previous studies addressing smoking cessation and GERD found conflicting results. One 
study found no influence of 24 hours refrainment from smoking on 24-hour pH-measurements of the 
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distal esophagus in 10 smokers with GERS.(22) Another study found no immediate effect of smoking 
cessation on total esophageal acid exposure in 8 smoking men with moderate to severe endoscopic 
evidence of GERD. (23) The third study, however, found a reduced distal esophageal acid exposure in 
14 smokers with reflux esophagitis who abstained from smoking for 48 hours.(24) Our study is the 
first epidemiological investigation testing whether tobacco smoking cessation improves GERS and the 
first study that evaluates such cessation in a long-term perspective.  
 
The results of our study suggest that tobacco smoking cessation may improve severe GERS among 
normal weight individuals in the general population. As this is an observational study, a causal 
relationship cannot be claimed, and we do not know if smoking cessation occurred before 
improvement of GERS or the other way around. However, the results are consistent with the 
pathophysiology (10-14) and a randomized controlled trial of smoking cessation would be very hard 
and unethical to perform. The study only considered frequency of tobacco smoking, not dose or time 
since cessation. However, pathophysiological data suggests that the effect of tobacco smoking is very 
short lived, so dose and time since cessation should be of less importance. In addition, daily smoking 
is a common cut-off level in observational study, making comparisons with other studies easier. We 
found no association between tobacco smoking cessation and improvement in minor GERS. This 
probably reflects the heterogenetic nature of individuals reporting minor GERS, including individuals 
with functional syndromes. These syndromes have other pathophysiological mechanisms, at least 
partly not related to gastroesophageal reflux or tobacco smoking. Due to the low absolute number of 
individuals, we defined the ‘exposure’ in this study to be a combination of those quitting smoking 
and those only reducing daily smoking to occasional smoking. Even so, we found an association 
between the ‘exposure’, i.e. reduced tobacco smoking, and the outcome, i.e. improved GERS. This 
suggests that total smoking cessation would increase the chance of success even more than apparent 
from our study. The improvement in GERS was limited to persons of normal weight using at least 
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weekly antireflux medication. The lack of improvement in overweight individuals might be explained 
by the strong association between BMI and GERS, which might dominate compared to the effect of 
tobacco smoking on GERS in overweight individuals. Thus, the pathophysiology of GERS is probably 
driven by the weight in overweight and obese individuals and smoking has a minor role, but in 
individuals of normal weight smoking has a more important role in the pathophysiology. The lack of 
improvement among those using no or less than weekly antireflux medication, suggests that the 
individuals with severe GERS have an advanced stage of GERD, i.e. esophagitis or symptoms related 
to the presence of hiatal hernia, which does not resolve only with tobacco smoking cessation. 
However, weight loss and tobacco smoking cessation might reduce the need for antireflux 
medication over time. In addition, these lifestyle measures are also advisable due to the effects on 
general health. As tobacco smoking as well as GERS is associated with adenocarcinoma of the distal 
esophagus and gastric cardia, persons with GERS should be advised to refrain from smoking.(16-19) 
The population-based design, argues for generalizability to the general Norwegian population and 
other Western populations of mainly Caucasians. 
 
In conclusion, while tobacco smoking cessation was not associated with any decrease in GERS among 
individuals with minor GERS, overweight, or those using antireflux medication less than weekly, an 
improvement in severe GERS was identified among normal weight individuals using regular antireflux 
medication. Tobacco smoking cessation might be beneficial in this latter group of patients suffering 
from gastroesophageal reflux.
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FIGURE LEGENDS 
 
Figure 1 Flowchart of study participants 
 
Figure 2 Odds ratio and 95% confidence interval (CI) of improvement in severe GERS by tobacco 
smoking cessation, comparing previous daily tobacco smokers with persistent daily tobacco smokers 
as reference. Restricted to those using at least weekly antireflux medication and stratified by body 
mass index (BMI). Model adjusted for sex, age, alcohol consumption, education, and physical 
exercise. 
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TABLES 
Table 1 Characteristics of study participants 
Tobacco smoking status Previous daily smokers (n=213) 
 
Persistent daily smokers (n=251) 
Antireflux medication* 
No or < weekly 
(n=86) 
 
≥ Weekly 
(n=127) 
 
No or < weekly 
(n=99) 
 
≥ Weekly 
(n=152) 
BMI† 
       
 
Mean (sd) 28.5 (4.7) 
 
29.2 (4.5) 
 
28.1 (5.0) 
 
28.9 (5.1) 
 
Median (range) 28.1 (18.7-47.2) 
 
29.0 (19.0-44.1) 
 
27.8 (18.9-49.3) 
 
28.0 (15.2-47.5) 
 
< 18.5, no. (%) 0 (0.0) 
 
0 (0.0) 
 
0 (0.0) 
 
2 (1.3) 
 
18.5-24.9, no. (%) 22 (25.6) 
 
20 (15.7) 
 
28 (28.3) 
 
30 (19.7) 
 
25.0-29.9, no. (%) 35 (40.7) 
 
55 (43.3) 
 
42 (42.4) 
 
69 (45.4) 
 
≥ 30.0, no. (%) 29 (33.7) 
 
49 (38.6) 
 
28 (28.3) 
 
51 (33.6) 
 
Missing, no. (%) 0 (0.0) 
 
3 (2.4) 
 
1 (1.0) 
 
0 (0.0) 
Sex, no. (%) 
       
 
Women 37 (43) 
 
54 (43) 
 
52 (53) 
 
92 (61) 
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Age, years 
       
 
Mean (sd) 55.7 (11.7) 
 
58.9 (9.9) 
 
51.8 (10.3) 
 
57.5 (10.3) 
 
Median (range) 55.3 (32.8-84.9) 
 
58.6 (34.3-84.7) 
 
51.3 (34.1-84.4) 
 
56.7 (31.9-87.8) 
Alcohol consumption, no. (%) 
       
 
< Weekly 51 (59.3) 
 
82 (64.6) 
 
65 (65.7) 
 
107 (70.4) 
 
≥ Weekly 34 (39.5) 
 
44 (34.6) 
 
34 (34.3) 
 
44 (28.9) 
 
Missing 1 (1.2) 
 
1 (0.8) 
 
0 (0.0) 
 
1 (0.7) 
Education, no. (%) 
       
 
≤ 12 years 67 (77.9) 
 
112 (88.2) 
 
91 (91.9) 
 
135 (88.8) 
 
> 12 years 17 (19.8) 
 
13 (10.2) 
 
7 (7.1) 
 
14 (9.2) 
 
Missing 2 (2.3) 
 
2 (1.6) 
 
1 (1.0) 
 
3 (2.0) 
Physical exercise, no. (%) 
       
 
< Weekly 28 (32.6) 
 
33 (26.0) 
 
38 (38.4) 
 
56 (36.8) 
 
≥ Weekly 58 (67.4) 
 
92 (72.4) 
 
61 (61.6) 
 
94 (61.8) 
 
Missing 0 (0.0) 
 
2 (1.6) 
 
0 (0.0) 
 
2 (1.3) 
* Antireflux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids  
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Participants with no information on antireflux medication were included in never or < weekly category 
† BMI: body mass index (kg/m2) 
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Table 2 Odds ratio (OR) with 95% confidence interval (CI) of improvement in severe GERS by tobacco smoking cessation, stratified by 
use of antireflux medication* 
    
Unadjusted 
 
Adjusted for sex and age 
 
Fully adjusted† 
Antireflux medication‡ 
 
No. OR 95% CI 
 
No. OR 95% CI 
 
No. OR 95% CI 
No or < weekly 
 
 
 
185 1.12 0.48 - 2.62 
 
185 1.06 0.45 - 2.52 
 
181 0.95 0.39 - 2.30 
≥ Weekly 
 
 
 
279 1.44 0.90 - 2.32 
 
279 1.62 0.99 - 2.65 
 
268 1.78 1.07 - 2.97 
* From severe heartburn or acid regurgitation (GERS) in HUNT 2, to no or minor GERS in HUNT 3/Mini-Q 
Comparing previous daily smokers with persistent daily smokers as reference 
† Adjusted for sex, age, body mass index, alcohol consumption, years of education, and physical exercise 
‡ Antireflux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids 
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Table 3 Odds ratio (OR) with 95% confidence interval (CI) of improvement in severe GERS by tobacco smoking cessation, stratified by 
use of antireflux medication and body mass index (BMI)* 
    
Unadjusted 
 
Adjusted for sex and age 
 
Fully adjusted† 
Antireflux medication‡ BMI 
 
No. OR 95% CI 
 
No. OR 95% CI 
 
No. OR 95% CI 
No or < weekly 
 
All 
 
185 1.12 0.48 - 2.62 
 
185 1.06 0.45 - 2.52 
 
181 0.95 0.39 - 2.30 
  
18.5-24.9 
 
50 1.06 0.21 - 5.30 
 
50 0.89 0.17 - 4.65 
 
49 0.80 0.13 - 5.08 
  
25.0-29.9 
 
77 1.29 0.33 - 5.00 
 
77 1.32 0.33 - 5.27 
 
63 1.13 0.27 - 4.75 
  
≥ 30.0 
 
57 1.04 0.23 - 4.64 
 
57 0.74 0.14 - 3.89 
 
57 0.90 0.16 - 5.17 
               ≥ Weekly 
 
All 
 
279 1.44 0.90 - 2.32 
 
279 1.62 0.99 - 2.65 
 
268 1.78 1.07 - 2.97 
  
18.5-24.9 
 
50 3.92 1.13 - 13.60 
 
50 4.70 1.22 - 18.18 
 
49 5.67 1.36 - 23.64 
  
25.0-29.9 
 
124 1.25 0.62 - 2.56 
 
124 1.20 0.57 - 2.53 
 
121 1.24 0.57 - 2.71 
  
≥ 30.0 
 
100 1.01 0.46 - 2.22 
 
100 1.28 0.55 - 2.99 
 
93 1.29 0.53 - 3.17 
* From severe heartburn or acid regurgitation (GERS) in HUNT 2, to no or minor GERS in HUNT 3/Mini-Q 
Comparing previous daily smokers with persistent daily smokers as reference 
† Adjusted for sex, age, alcohol consumption, years of education, and physical exercise 
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‡ Antireflux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids 
 
 
Participants reporting GERS in both HUNT 2 and HUNT 3/Mini-Q 
N=29,610 
No or minor GERS in HUNT 2 
n=28,057 (95%) 
Severe GERS in HUNT 2 
n=1553 (5%) 
Missing smoking status in HUNT 2 
n=8 (1%) 
Previous or never smokers in HUNT 2 
n=1059 (68%) 
Daily smokers in HUNT 2 
n=486 (31%) 
Missing smoking status in HUNT 3/Mini-Q 
n=22 (4%) 
Previous daily smokers in HUNT 3/Mini-Q 
n=213 (44%) 
Persistent daily smokers in HUNT 3/Mini-Q 
n=251 (52%) 
No or < weekly 
antireflux 
medication in 
HUNT 3/Mini-Q 
n=86 (40%) 
≥ Weekly 
antireflux 
medication in 
HUNT 3/Mini-Q 
n=127 (60%) 
No or < weekly 
antireflux 
medication in 
HUNT 3/Mini-Q 
n=99 (39%) 
≥ Weekly 
antireflux 
medication in 
HUNT 3/Mini-Q 
n=152 (61%) 

